This page lists the gynaecology hospitals in our directory offering Amniocentesis in Delhi NCR, India, including Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute and others. Each listing links through to the hospital's full profile page.
Ask us about amniocentesis in Delhi NCR, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 35 accredited hospitals for Gynaecology in Delhi NCR, India
Featured🇮🇳 Apollo Hospitals
Ranks #1 in this list by listed rating (4.9/5 from 1240 reviews).
🇮🇳 Medanta - The Medicity
Ranks #2 in this list by listed rating (4.9/5 from 2150 reviews).
🇮🇳 Artemis Hospital
Ranks #3 in this list by listed rating (4.9/5 from 64 reviews).
🇮🇳 Fortis Memorial Research Institute
Ranks #4 in this list by listed rating (4.8/5 from 1100 reviews).
🇮🇳 Max Super Specialty Hospital
Ranks #5 in this list by listed rating (4.8/5 from 1300 reviews).
🇮🇳 All India Institute of Medical Sciences (AIIMS)
Ranks #6 in this list by listed rating (4.7/5 from 3500 reviews).
🇮🇳 CK Birla Hospital
Ranks #7 in this list by listed rating (4.7/5 from 162 reviews).
🇮🇳 Centre for Sight
Ranks #8 in this list by listed rating (4.7/5 from 181 reviews).
🇮🇳 Max Super Specialty Hospital, Gurgaon
Ranks #9 in this list by listed rating (4.6/5 from 95 reviews).
🇮🇳 Max Super Speciality Hospital, Patparganj
Ranks #10 in this list by listed rating (4.6/5 from 97 reviews).
🇮🇳 Primus Super Speciality Hospital
Ranks #11 in this list by listed rating (4.6/5 from 142 reviews).
🇮🇳 PSRI Multispeciality Hospital
Ranks #12 in this list by listed rating (4.6/5 from 318 reviews).
🇮🇳 Fortis Hospital, Shalimar Bagh
Ranks #13 in this list by listed rating (4.5/5 from 68 reviews).
🇮🇳 Sarvodaya Hospital
Ranks #14 in this list by listed rating (4.5/5 from 74 reviews).
🇮🇳 Indian Spinal Injuries Center
Ranks #15 in this list by listed rating (4.5/5 from 76 reviews).
🇮🇳 Max Super Speciality Hospital, Shalimar Bagh
Ranks #16 in this list by listed rating (4.5/5 from 82 reviews).
🇮🇳 Fortis Hospital, Noida
Ranks #17 in this list by listed rating (4.5/5 from 88 reviews).
🇮🇳 Venkateshwar Hospital
Ranks #18 in this list by listed rating (4.5/5 from 69 reviews).
🇮🇳 CK Birla Hospital
Ranks #19 in this list by listed rating (4.5/5 from 72 reviews).
🇮🇳 Fortis Flt. Lt. Rajan Dhall Hospital
Ranks #20 in this list by listed rating (4.5/5 from 75 reviews).
🇮🇳 Asian Institute of Medical Sciences
Ranks #21 in this list by listed rating (4.5/5 from 119 reviews).
🇮🇳 Manipal Hospitals Dwarka
Ranks #22 in this list by listed rating (4.4/5 from 54 reviews).
🇮🇳 Sir Ganga Ram Hospital
Ranks #23 in this list by listed rating (4.4/5 from 24 reviews).
🇮🇳 Fortis Escorts Hospital
Ranks #24 in this list by listed rating (4.4/5 from 31 reviews).
🇮🇳 Marengo Asia Hospitals
Ranks #25 in this list by listed rating (4.4/5 from 54 reviews).
🇮🇳 Yatharth Super Specialty Hospital
Ranks #26 in this list by listed rating (4.4/5 from 61 reviews).
🇮🇳 Paras Hospitals
Ranks #27 in this list by listed rating (4.4/5 from 59 reviews).
🇮🇳 Fortis Hospital Manesar
Ranks #28 in this list by listed rating (4.4/5 from 74 reviews).
🇮🇳 Marengo Asia Hospitals Gurgaon
Ranks #29 in this list by listed rating (4.4/5 from 103 reviews).
🇮🇳 Metro Hospital Noida
Ranks #30 in this list by listed rating (4.4/5 from 121 reviews).
🇮🇳 Sharda Hospital
Ranks #31 in this list by listed rating (4.4/5 from 130 reviews).
🇮🇳 Fortis Hospital, Greater Noida
Ranks #32 in this list by listed rating (4.3/5 from 28 reviews).
🇮🇳 Fortis Escorts Hospital Jaipur
Ranks #33 in this list by listed rating (4.3/5 from 132 reviews).
🇮🇳 Max Super Speciality Hospital, Saket
Ranks #34 in this list by listed rating (3.8/5 from 49 reviews).
🇮🇳 BLK-Max Super Speciality Hospital
Ranks #35 in this list by listed rating (3.8/5 from 48 reviews).
How we selected these hospitals
A hospital appears on this page when Gynaecology is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Amniocentesis in Delhi NCR, India?
Choosing the right hospital for amniocentesis is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include gynaecology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Amniocentesis
Amniocentesis is a precision prenatal diagnostic procedure in which a fine needle is used under continuous ultrasound guidance to aspirate a small volume of amniotic fluid, enabling chromosomal karyotyping, FISH analysis, microarray-based comparative genomic hybridization (aCGH), and biochemical assays with a diagnostic accuracy exceeding 99%. The procedure carries a procedure-related pregnancy loss rate of approximately 0.1–0.3% in high-volume centers, and is performed by experienced maternal-fetal medicine (MFM) specialists across JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed facilities in the UAE. GAF Healthcare connects international patients to elite fetal medicine units in both destinations, offering seamless coordination, transparent pricing, and dedicated multilingual patient support from first inquiry through final results. Hospital Stay: 0–1 days (typically an outpatient or day-care procedure; overnight observation only if clinically indicated) • Total Stay in Country (Fit-to-Fly): 3–7 days (short-haul); 7–10 days recommended before long-haul international flights, pending absence of post-procedural complications and receipt of preliminary FISH results • Success Rate: Diagnostic accuracy >99%; procedure-related fetal loss rate 0.1–0.3% at accredited high-volume centers
Clinical Overview
Amniocentesis is a minimally invasive, ultrasound-guided transabdominal procedure performed between 15 and 20 weeks of gestation (mid-trimester amniocentesis), or occasionally in the third trimester for assessments of fetal lung maturity or infection. Under real-time sonographic visualization, a 22-gauge spinal needle is advanced through the maternal abdominal wall and uterus into the amniotic sac, and approximately 15–20 mL of amniotic fluid is withdrawn. This fluid contains desquamated fetal cells (amniocytes) and cell-free fetal DNA, which serve as the substrate for a spectrum of diagnostic analyses including G-banded karyotyping (resolution ~5–10 Mb), chromosomal microarray analysis (aCGH or SNP array, resolution ~50–100 kb), quantitative fluorescence PCR (QF-PCR) for rapid aneuploidy detection (trisomies 13, 18, 21; sex chromosome abnormalities), whole-exome sequencing (WES) in selected cases, and biochemical tests such as alpha-fetoprotein (AFP) and acetylcholinesterase for neural tube defect confirmation. The physiological rationale for offering amniocentesis rests on a risk-stratified framework. Advanced maternal age (≥35 years at delivery), a high-risk first-trimester combined screening result (nuchal translucency ≥3.5 mm, abnormal PAPP-A or free β-hCG), an abnormal cell-free fetal DNA (cfDNA/NIPT) result, a structural anomaly detected on targeted anomaly ultrasound, a known parental chromosomal rearrangement or autosomal recessive carrier status, or a prior pregnancy affected by a chromosomal or single-gene disorder each represent evidence-based indications where the diagnostic benefit substantially outweighs procedural risk. The Fetal Medicine Foundation (FMF) algorithm and ACOG/RCOG guidelines form the international framework guiding patient selection. The global standard of care mandates that amniocentesis be performed exclusively by credentialed maternal-fetal medicine specialists or trained fetal medicine consultants using high-resolution ultrasound equipment (≥18 MHz linear or curvilinear transducers), with continuous needle visualization, avoidance of the placenta and umbilical cord insertion whenever possible, single-needle insertion technique, and anti-D immunoglobulin prophylaxis (300 μg IM) administered to all RhD-negative unsensitized women within 72 hours of the procedure. Laboratories analyzing the amniotic fluid should hold ISO 15189 accreditation and report QF-PCR results within 24–48 hours and full karyotype/microarray results within 10–14 days.
Who is a Candidate?
• ELIGIBLE CANDIDATES (Indications): • Advanced maternal age: ≥35 years at the estimated date of delivery • High-risk first-trimester combined screening: risk ratio ≥1:150 for trisomy 21, 18, or 13 based on nuchal translucency + serum biochemistry (PAPP-A, free β-hCG) ± nasal bone, ductus venosus, tricuspid regurgitation • Abnormal or high-risk cfDNA (NIPT) result requiring diagnostic confirmation • Structural fetal anomaly identified on second-trimester targeted ultrasound (e.g., cardiac defect, choroid plexus cysts, ventriculomegaly, echogenic bowel, short femur) • Known parental balanced chromosomal rearrangement (reciprocal or Robertsonian translocation, inversion) • Both parents are confirmed carriers of an autosomal recessive condition (e.g., cystic fibrosis, spinal muscular atrophy, thalassemia) or the mother is a carrier of an X-linked condition • Previous pregnancy affected by a chromosomal aneuploidy or pathogenic copy number variant • Suspected fetal infection (CMV, toxoplasmosis) requiring amniotic fluid PCR • Third-trimester indication: assessment of fetal lung maturity (lamellar body count, lecithin-sphingomyelin ratio) or therapeutic decompression in polyhydramnios • REQUIRED PRE-PROCEDURE DIAGNOSTICS: • High-resolution obstetric ultrasound (placental localization, liquor volume, fetal presentation, cord insertion mapping) • First-trimester combined or second-trimester quadruple/integrated screening results • cfDNA/NIPT report (if previously performed) • Complete blood count, blood group and Rh factor, indirect Coombs test • Maternal infection screen: Hepatitis B surface antigen, HIV, RPR/VDRL (to guide infection-control needle precautions) • Genetic counseling session (mandatory pre-procedure): review of risk-benefit ratio, procedural alternatives, and implications of possible results • CONTRAINDICATIONS / SITUATIONS REQUIRING CAUTION: • Active maternal genital herpes outbreak or known HIV viremia without suppressive therapy (relative contraindication; specialist risk assessment required) • Placenta previa overlying the only accessible needle path (technical contraindication; alternative approach or procedure reassessment needed) • Severe oligohydramnios making safe needle placement hazardous • Gestational age <15+0 weeks (early amniocentesis <15 weeks is associated with a significantly higher fetal loss rate and club foot risk; chorionic villus sampling (CVS) preferred before 14 weeks) • Maternal RhD sensitization with existing anti-D antibodies (anti-D prophylaxis not required, but close MFM oversight needed) • Significant uterine fibroids obstructing all safe needle trajectories
Treatment Options & Approaches
STANDARD MID-TRIMESTER AMNIOCENTESIS (15–20 WEEKS): The foundational technique involves a single 22-gauge, 9–15 cm spinal needle advanced under continuous real-time ultrasound guidance in a freehand technique (preferred over needle guides for superior maneuverability). The operator maps the largest, most accessible amniotic fluid pocket away from the fetal face and umbilical cord insertion, selects a transplacental or paraplacental approach based on placental location (transplacental crossing is acceptable and does not significantly increase risk when performed by experienced operators), inserts the needle in a single pass, removes the stylet, and aspirates 1 mL per gestational week (approximately 15–20 mL total). The first 0.5–1 mL is discarded to minimize maternal cell contamination. No local anesthetic is routinely required; some centers offer subcutaneous lidocaine for anxious patients. ADVANCED DIAGNOSTIC PANELS AVAILABLE POST-SAMPLING: • QF-PCR / FISH (Rapid Aneuploidy Detection): 24–48 hour turnaround; detects trisomies 21, 18, 13, and sex chromosome aneuploidies with >99% sensitivity and specificity. Ideal for time-sensitive decision-making. • G-Banded Karyotype (Conventional Cytogenetics): 10–14 days; identifies numerical and structural chromosomal abnormalities at ~5–10 Mb resolution. • Chromosomal Microarray Analysis (aCGH/SNP Array): 10–14 days; detects submicroscopic copy number variants (deletions, duplications) and regions of homozygosity (ROH) associated with autosomal recessive conditions; now recommended as a first-line adjunct to karyotyping by ACOG and SMFM. • Whole-Exome Sequencing (WES) of Amniocytes: 4–8 weeks; reserved for cases with ultrasound-detected fetal anomalies and a normal karyotype/microarray, where a single-gene (Mendelian) disorder is suspected. • Targeted Molecular Testing: MLPA, Sanger sequencing, or next-generation sequencing panels for specific conditions (e.g., CFTR mutation analysis, SMN1 copy number, beta-globin variants) when parental carrier status is known. • Amniotic Fluid AFP + Acetylcholinesterase: Biochemical confirmation of open neural tube defects and ventral wall defects. • Amniotic Fluid PCR for Fetal Infection: CMV, toxoplasma, parvovirus B19, Zika virus. TECHNICAL ADJUNCTS & INNOVATIONS: • Three-Port Continuous Ultrasound Guidance: Real-time needle tip visualization throughout insertion using high-frequency curvilinear probes with Doppler color-flow mapping to avoid cord vessels. • Twin/Multiple Gestation Amniocentesis: Each sac is sampled separately using a dye-injection technique (1 mL indigo carmine into the first sac after sampling to confirm separate access to the second sac); single-operator sequential technique or two-operator approach. • Amniocentesis Under Difficult Conditions: In cases of anterior fibroids, obesity (BMI >40), or oligohydramnios, experienced MFM specialists may employ rotational techniques, lateral approach, or defer to a tertiary center with 3D ultrasound guidance capability. • Early Amniocentesis (<15 weeks): Largely abandoned due to elevated post-procedural talipes equinovarus risk and culture failure rates; CVS remains the preferred diagnostic procedure before 14 weeks. POST-PROCEDURE CARE: Patients are observed for 30–60 minutes post-procedure with a confirmatory ultrasound to document fetal cardiac activity and amniotic fluid volume. Anti-D immunoglobulin 300 μg IM is administered to all RhD-negative unsensitized mothers. Patients are counseled to rest for 24 hours, avoid strenuous activity or sexual intercourse for 48 hours, report any fluid leakage per vagina, bleeding, uterine cramping persisting >6 hours, fever >38°C, or reduced fetal movements immediately.
Recovery
STEP 1 — PRE-TRAVEL PREPARATION (1–2 WEEKS BEFORE DEPARTURE): GAF Healthcare's clinical coordination team reviews the patient's existing prenatal records, NIPT/cfDNA results, and ultrasound reports. A telemedicine pre-consultation is arranged with the receiving maternal-fetal medicine specialist. The genetic counseling session (mandatory) is conducted remotely or in-person on arrival. The medical visa application (India e-Medical Visa or UAE visit/tourist visa) is initiated with GAF's support. Accommodation and airport transfers are booked. The patient is advised to compile blood group card, previous obstetric reports, and vaccination records. STEP 2 — ARRIVAL & PRE-PROCEDURE ASSESSMENT (DAY 1): The patient is received at the airport by a GAF healthcare coordinator and transferred to the partner hospital or hotel. On Day 1, a dedicated admissions nurse registers the patient and a repeat targeted ultrasound is performed by the MFM specialist to confirm gestational age, placental location, fluid volume, and optimal needle entry site. Blood group confirmation and Rh factor are verified. Genetic counseling is completed in the patient's preferred language via a GAF-assigned interpreter if required. Informed consent is obtained with discussion of procedural risks, alternative options (NIPT as screening only; continuing pregnancy without testing), and the full menu of available diagnostic panels. The procedure is scheduled for Day 2 (or sometimes later the same day if the center operates on a same-day protocol). STEP 3 — THE PROCEDURE (DAY 2; DURATION: 10–20 MINUTES): The patient attends the procedure suite (no fasting required; the procedure is performed under ultrasound guidance only, not general anesthesia). She is positioned supine with a slight left lateral tilt to decompress the inferior vena cava. The abdomen is cleaned with antiseptic solution and draped. Under continuous real-time ultrasound guidance, the MFM specialist advances a 22-gauge needle into the selected amniotic fluid pocket, aspirates 15–20 mL of fluid, and withdraws the needle in a controlled single motion. Total needle time is typically under 60 seconds. The sample is labeled and immediately transported to the accredited cytogenetics/molecular genetics laboratory. Post-procedure ultrasound confirms fetal cardiac activity. Anti-D is administered if indicated. The patient is observed for 30–60 minutes before discharge. STEP 4 — IMMEDIATE POST-PROCEDURE PERIOD (DAY 2–4): The patient is discharged to hotel accommodation (or home if locally resident) with written and verbal aftercare instructions. Bed rest is recommended for the remainder of Day 2. Mild lower abdominal cramping and very light spotting are expected for 24–48 hours and are normal. The patient is given a 24-hour emergency contact number for the MFM unit. A follow-up ultrasound is optionally offered on Day 3–4 to re-confirm fetal wellbeing before any planned travel. STEP 5 — RESULTS & COUNSELING (DAY 2 THROUGH DAY 14): • QF-PCR / FISH results: Available within 24–48 hours; communicated via secure messaging and a brief telemedicine call with the specialist. • Full karyotype and/or chromosomal microarray results: Available within 10–14 days; a formal genetic counseling session is arranged (in-person if still in country; via telemedicine if the patient has returned home). • WES results (if requested): 4–8 weeks; managed via telemedicine follow-up coordinated by GAF Healthcare. STEP 6 — FITNESS TO FLY & DEPARTURE: In uncomplicated cases, patients are considered fit for short-haul flights (≤4 hours) by Day 3–5 and for long-haul international flights by Day 7–10, provided there is no fluid leakage, persistent cramping, bleeding, or fever, and the follow-up ultrasound confirms a viable intrauterine pregnancy with normal fluid volume. GAF provides a medical fitness-to-fly certificate from the treating MFM specialist for airline compliance. STEP 7 — POST-RETURN FOLLOW-UP: GAF Healthcare's telemedicine platform facilitates ongoing result communication, additional genetic counseling if results are abnormal, and referral coordination with the patient's home obstetrician or clinical geneticist. A structured summary report, including procedural details, laboratory accreditation documentation, and result interpretation, is provided in the patient's language.
Risks to be aware of
Amniocentesis is among the safest invasive prenatal diagnostic procedures when performed by trained maternal-fetal medicine specialists under continuous ultrasound guidance, but it is not without risk and all patients must be counseled transparently before consenting. PROCEDURE-RELATED PREGNANCY LOSS: The most significant risk is fetal loss (miscarriage or stillbirth) attributable to the procedure. Contemporary high-volume center data cite a background-adjusted procedure-related loss rate of 0.1–0.3% (approximately 1 in 300–1,000 procedures). This risk is higher when performed by low-volume operators, at gestational ages below 15 weeks, or in the context of severe oligohydramnios. Patients must understand that some miscarriages occurring after amniocentesis are unrelated to the procedure and represent background pregnancy loss for the gestational age. AMNIOTIC FLUID LEAKAGE: Transient leakage of amniotic fluid per vagina occurs in approximately 1–2% of cases. The majority seal spontaneously within 48–72 hours. Persistent leakage may indicate preterm prelabor rupture of membranes (PPROM), which requires urgent obstetric assessment. CHORIOAMNIONITIS: Uterine infection following amniocentesis is rare (<0.1%) when strict aseptic technique is used, but it is a serious complication that can lead to preterm labor, sepsis, and fetal loss. Fever, uterine tenderness, and maternal tachycardia after the procedure warrant immediate medical evaluation. FETAL INJURY: Direct needle contact with the fetus is rare with continuous ultrasound guidance; fetal skin dimpling at the needle entry site has been reported in extremely rare cases. RH SENSITIZATION: In RhD-negative mothers, fetal-maternal hemorrhage can occur; anti-D immunoglobulin prophylaxis (300 μg IM within 72 hours) effectively mitigates this risk. PSYCHOLOGICAL DISTRESS: Awaiting diagnostic results for 10–14 days creates significant anxiety. GAF Healthcare provides psychological support resources and expedited result communication to minimize distress. DIAGNOSTIC LIMITATIONS: Chromosomal microarray detects variants of uncertain significance (VOUS) in approximately 1–2% of cases, which can cause additional parental anxiety without definitive clinical guidance. Full karyotype cannot detect single-gene disorders unless targeted molecular testing is additionally requested. Confined placental mosaicism or true fetal mosaicism detected at amniocentesis requires careful specialist interpretation. Patients must receive pre-procedure genetic counseling that addresses all of these diagnostic nuances. COUNTRY-SPECIFIC LEGAL CONTEXT: It is critical to note that in India, the Preconception and Prenatal Diagnostic Techniques (PCPNDT) Act strictly prohibits sex determination for non-medical purposes. Amniocentesis in India may only be performed for legitimate medical indications as outlined above. GAF Healthcare and all partner hospitals fully comply with PCPNDT regulations.
Why GAF Healthcare
GAF Healthcare provides a fully integrated non-medical support ecosystem designed to eliminate logistical barriers for international patients traveling to India or the UAE for amniocentesis. VISA ASSISTANCE — INDIA: GAF Healthcare facilitates the Indian e-Medical Visa application for the patient and up to two attendants (spouse/family member). The e-Medical Visa is available to nationals of most countries, processed online within 1–4 business days, valid for 60 days with triple-entry, and costs approximately USD 25 per person. GAF's documentation team prepares the hospital invitation letter, appointment confirmation, and procedural justification letter required for the visa application portal. For patients from countries not eligible for e-Medical Visa, GAF's ground team liaisons with the relevant Indian embassy. VISA ASSISTANCE — UAE: Nationals from over 50 countries (including the EU, UK, USA, Canada, Australia, GCC states) receive visa-on-arrival or visa-free access to the UAE for 30–90 days. GAF coordinates visa-on-arrival facilitation letters for eligible patients and processes pre-entry UAE tourist visas for nationals requiring advance application. No medical visa category exists in the UAE; standard tourist or visit visas are used. AIRPORT TRANSFERS & IN-COUNTRY TRANSPORT: GAF provides private, air-conditioned vehicle transfers between the airport, hospital, and accommodation at all hours. All drivers are vetted by GAF's ground operations team and carry patient information cards in English and the patient's language. Return transfers to the airport are coordinated to align with the patient's fitness-to-fly clearance date. DEDICATED MULTILINGUAL PATIENT COORDINATORS: Each patient is assigned a named GAF Healthcare coordinator fluent in the patient's language (Arabic, Russian, French, Swahili, Bengali, and other languages available). The coordinator accompanies the patient to consultations, procedure appointments, and administrative processes, ensuring no communication gap between the clinical team and the patient. Certified medical interpreters are available for rare languages on 24-hour notice. ACCOMMODATION: GAF arranges accommodation for the patient and one to two attendants in partner hotels located within 5–15 minutes of the treating hospital, ranging from 3-star to 5-star properties depending on patient preference and budget. Post-procedure, hotel rooms with ground-floor or lift access and proximity to hospital emergency services are prioritized. Meal preferences (dietary, religious) are communicated to the hotel in advance. TELEMEDICINE & POST-DEPARTURE RESULT COMMUNICATION: Given that full karyotype and microarray results take 10–14 days — and most patients will have returned home before results are finalized — GAF Healthcare's secure telemedicine platform enables the treating MFM specialist or genetic counselor to deliver and explain results via video consultation. All reports are uploaded to the patient's secure GAF portal and shared with the patient's home obstetrician on request. TRANSPARENCY & NO HIDDEN FEES: GAF Healthcare provides an itemized cost estimate before any commitment, covering consultation fees, procedure fees, laboratory panel costs, anti-D immunoglobulin, post-procedure ultrasound, and logistics. There are no referral commissions concealed in the pricing. Patients may compare quotes from multiple GAF partner hospitals.
Common questions about Amniocentesis
What is the cost of amniocentesis in India versus the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after amniocentesis?
What is the success rate of amniocentesis, and how reliable are the results?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Amniocentesis in Delhi NCR, India
Discover the Top Hospitals for Amniocentesis in Delhi NCR, India
This page lists 35 accredited gynaecology hospitals in Delhi NCR, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about amniocentesis in Delhi NCR, India
How many gynaecology hospitals are listed in Delhi NCR, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there gynaecology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for amniocentesis in Delhi NCR, India.
Contact us to report an inaccuracy on this page.